COVIDpro: Database for Mining Protein Dysregulation in Patients with COVID-19

The ongoing pandemic of the coronavirus disease 2019
(COVID-19)
caused by the severe acute respiratory syndrome coronavirus 2 still
has limited treatment options. Our understanding of the molecular
dysregulations that occur in response to infection remains incomplete.
We developed a web application COVIDpro (https://www.guomics.com/covidPro/) that includes proteomics data obtained from 41 original studies
conducted in 32 hospitals worldwide, involving 3077 patients and covering
19 types of clinical specimens, predominantly plasma and serum. The
data set encompasses 53 protein expression matrices, comprising a
total of 5434 samples and 14,403 unique proteins. We identified a
panel of proteins that exhibit significant dysregulation, enabling
the classification of COVID-19 patients into severe and non-severe
disease categories. The proteomic signatures achieved promising results
in distinguishing severe cases, with a mean area under the curve of
0.87 and accuracy of 0.80 across five independent test sets. COVIDpro
serves as a valuable resource for testing hypotheses and exploring
potential targets for novel treatments in COVID-19 patients.